|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Valsartan#Adverse Reactions]] |
| {{Valsartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| ===6.1 Clinical Studies Experience===
| |
| | |
| Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
| |
| | |
| ====Adult Hypertension====
| |
| | |
| Diovan (valsartan) has been evaluated for safety in more than 4,000 patients, including over 400 treated for over 6 months, and more than 160 for over 1 year. Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall incidence of adverse reactions with Diovan was similar to placebo.
| |
| | |
| The overall frequency of adverse reactions was neither dose-related nor related to gender, age, race, or regimen. Discontinuation of therapy due to side effects was required in 2.3% of valsartan patients and 2.0% of placebo patients. The most common reasons for discontinuation of therapy with Diovan were headache and [[dizziness]].
| |
| | |
| The adverse reactions that occurred in placebo-controlled clinical trials in at least 1% of patients treated with Diovan and at a higher incidence in valsartan (n=2,316) than placebo (n=888) patients included viral infection (3% vs. 2%), fatigue (2% vs. 1%), and abdominal pain (2% vs. 1%).
| |
| | |
| Headache, [[dizziness]], [[upper respiratory infection]], [[cough]], [[diarrhea]], [[rhinitis]], [[sinusitis]], [[nausea]], [[pharyngitis]], [[edema]], and [[arthralgia]] occurred at a more than 1% rate but at about the same incidence in placebo and valsartan patients.
| |
| | |
| In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of dry cough was significantly greater in the ACE-inhibitor group (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%). In a 129-patient trial limited to patients who had had dry cough when they had previously received ACE inhibitors, the incidences of cough in patients who received valsartan, HCTZ, or lisinopril were 20%, 19%, and 69% respectively (p <0.001).
| |
| | |
| Dose-related orthostatic effects were seen in less than 1% of patients. An increase in the incidence of dizziness was observed in patients treated with Diovan 320 mg (8%) compared to 10 to 160 mg (2% to 4%).
| |
| | |
| Diovan has been used concomitantly with [[hydrochlorothiazide]] without evidence of clinically important adverse interactions.
| |
| | |
| Other adverse reactions that occurred in controlled clinical trials of patients treated with Diovan (>0.2% of valsartan patients) are listed below. It cannot be determined whether these events were causally related to Diovan.
| |
| | |
| '''Body as a Whole''': [[Allergic reaction]] and [[asthenia]]
| |
| | |
| '''Cardiovascular''': [[Palpitations]]
| |
| | |
| '''Dermatologic''': [[Pruritus]] and [[rash]]
| |
| | |
| '''Digestive''': [[Constipation]], dry mouth, [[dyspepsia]], and [[flatulence]]
| |
| | |
| '''Musculoskeletal''': Back pain, muscle cramps, and [[myalgia]]
| |
| | |
| '''Neurologic and Psychiatric''': [[Anxiety]], [[insomnia]], [[paresthesia]], and [[somnolence]]
| |
| | |
| '''Respiratory''': [[Dyspnea]]
| |
| | |
| '''Special Senses''': [[Vertigo]]
| |
| | |
| '''Urogenital''': [[Impotence]]
| |
| | |
| Other reported events seen less frequently in clinical trials included chest pain, [[syncope]], [[anorexia]], [[vomiting]], and [[angioedema]].
| |
| | |
| ====Pediatric Hypertension====
| |
| | |
| Diovan has been evaluated for safety in over 400 pediatric patients aged 6 to 17 years and more than 160 pediatric patients aged 6 months to 5 years. No relevant differences were identified between the adverse experience profile for pediatric patients aged 6-16 years and that previously reported for adult patients. Headache and hyperkalemia were the most common adverse events suspected to be study drug-related in older children (6 to 17 years old) and younger children (6 months to 5 years old), respectively. Hyperkalemia was mainly observed in children with underlying renal disease. Neurocognitive and developmental assessment of pediatric patients aged 6 to 16 years revealed no overall clinically relevant adverse impact after treatment with Diovan for up to 1 year.
| |
| | |
| Diovan is not recommended for pediatric patients under 6 years of age. In a study (n=90) of pediatric patients (1-5 years), two deaths and three cases of on-treatment transaminase elevations were seen in the one-year open-label extension phase. These 5 events occurred in a study population in which patients frequently had significant co-morbidities. A causal relationship to Diovan has not been established. In a second study in which 75 children aged 1 to 6 years were randomized, no deaths and one case of marked liver transaminase elevations occurred during a 1 year open-label extension.
| |
| | |
| ====Heart Failure====
| |
| | |
| The adverse experience profile of Diovan in heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the Valsartan Heart Failure Trial, comparing valsartan in total daily doses up to 320 mg (n=2,506) to placebo (n=2,494), 10% of valsartan patients discontinued for adverse reactions vs. 7% of placebo patients.
| |
| | |
| The table shows adverse reactions in double-blind short-term heart failure trials, including the first 4 months of the Valsartan Heart Failure Trial, with an incidence of at least 2% that were more frequent in valsartan-treated patients than in placebo-treated patients. All patients received standard drug therapy for heart failure, frequently as multiple medications, which could include [[diuretics]], digitalis, [[beta-blockers]]. About 93% of patients received concomitant ACE inhibitors.
| |
| | |
| {|
| |
| |[[File:Valsartan03.png|thumb|800px]]
| |
| |}
| |
| | |
| | |
| | |
| Discontinuations occurred in 0.5% of valsartan-treated patients and 0.1% of placebo patients for each of the following: elevations in creatinine and elevations in potassium.
| |
| | |
| Other adverse reactions with an incidence greater than 1% and greater than placebo included [[headache]] NOS, [[nausea]], renal impairment NOS, [[syncope]], blurred vision, upper abdominal pain and [[vertigo]]. (NOS = not otherwise specified).
| |
| | |
| From the long-term data in the Valsartan Heart Failure Trial, there did not appear to be any significant adverse reactions not previously identified.
| |
| | |
| ====Post-Myocardial Infarction====
| |
| | |
| The safety profile of Diovan was consistent with the pharmacology of the drug and the background diseases, cardiovascular risk factors, and clinical course of patients treated in the post-[[myocardial infarction]] setting. The table shows the percent of patients discontinued in the valsartan and [[captopril]]-treated groups in the Valsartan in Acute Myocardial Infarction Trial (VALIANT) with a rate of at least 0.5% in either of the treatment groups.
| |
| | |
| Discontinuations due to renal dysfunction occurred in 1.1% of valsartan-treated patients and 0.8% of captopril-treated patients.
| |
| | |
| {|
| |
| |[[File:Valsartan04.png|thumb|800px]]
| |
| |}
| |
| | |
| ===6.2 Post-Marketing Experience===
| |
| The following additional adverse reactions have been reported in post-marketing experience:
| |
| | |
| Hypersensitivity: There are rare reports of [[angioedema]]. Some of these patients previously experienced [[angioedema]]with other drugs including ACE inhibitors. Diovan should not be re-administered to patients who have had [[angioedema]].
| |
| | |
| '''Digestive''': Elevated liver enzymes and very rare reports of [[hepatitis]]
| |
| | |
| '''Renal''': [[Impaired renal function]], [[renal failure]]
| |
| | |
| '''Clinical Laboratory Tests''': [[Hyperkalemia]]
| |
| | |
| '''Dermatologic''': [[Alopecia]]
| |
| | |
| '''Blood and Lymphatic''': There are very rare reports of [[thrombocytopenia]]
| |
| | |
| '''Vascular''': Vasculitis
| |
| | |
| Rare cases of [[rhabdomyolysis]] have been reported in patients receiving [[angiotensin]] II receptor blockers.
| |
| | |
| Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<ref name="dailymed.nlm.nih.gov">{{Citace elektronické monografie | příjmení = | jméno = | titul = DIOVAN (VALSARTAN) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ddba454-f3e6-43c2-a7a6-58365d297213 | vydavatel = | datum vydání = | datum aktualizace = | datum přístupu = 2014-02-24 }}</ref>
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Amides]]
| |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Novartis]]
| |
| [[Category:Tetrazoles]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |